Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00221312|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : May 8, 2008
This is a study to determine if Fosamax (alendronate), a medication approved by the Food and Drug Administration (FDA) for the prevention and treatment of osteoporosis in postmenopausal women, is effective in decreasing the rate of bone loss which often begins to increase in the three to five years preceding the menopause (perimenopausal transition).
During the three to five years prior to the menopause, the rate of bone loss increases. One way that physicians treat this is with oral contraceptive medication. However, the incidence of complications from oral contraceptives after the age of 40 increases. Therefore, a non-hormonal means of preventing bone loss should be useful. Fosamax (alendronate) is in a class of compounds called bisphosphonates. This study is being done to determine whether Fosamax can be used to prevent the increased rate of bone loss during the perimenopausal transition.
|Condition or disease||Intervention/treatment|
|Perimenopausal Bone Loss||Drug: Fosamax|
|Study Type :||Observational|
|Actual Enrollment :||48 participants|
|Observational Model:||Case Control|
|Official Title:||Alendronate to Prevent Perimenopausal Transition Bone Loss|
|Study Start Date :||May 2002|
|Actual Study Completion Date :||July 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00221312
|United States, California|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Robert B. Jaffe, M.D.||University of California, San Francisco|